Anavex Life Sciences 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Anavex Life Sciences 's ROA in the third quarter of 2026?
Anavex Life Sciences Corp recorded a cumulative net loss of $-13 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -11.37%.

However, within the Healthcare sector 357 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 3908 to 4402.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter
Y / Y Total Assets Change	18.07 %	10.61 %	-23.42 %	-23.42 %	-27.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-13	-34	-40	-46	-48
Return On Assets (TTM)	-11.37 %	-31.02 %	-37.4 %	-40.42 %	-39.27 %
AVXL's Total Ranking	# 4402	# 3908	# 3930	# 3948	# 4530
Total Assets (TTM) in million	121	130	104	104	102
Seq. Total Assets Change	-6.66 %	24.8 %	0 %	1.35 %	-12.56 %
Seq. Net Income Change	-	-	-	-	-

AVXL's 5 Years Annual ROA >> Back to AVXL Management Effectiveness >> Compare AVXL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 39
Sector	# 358
Overall	# 3768

Return On Assets Statistics
High	Average	Low
-11.41 %	-252.33 %	-5101.19 %
(Jun 30 2026)		(Jun 30 2012)

Financial Statements
Anavex Life Sciences 's Assets	$ 121 million	AVXL's Balance sheet
Anavex Life Sciences 's Income	$ 8 million	Quarterly AVXL's Income Statement
AVXL's Income by Division		See AVXL's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021
Y / Y Total Assets Change	-23.42 %	-12.19 %	1.1 %	-5.51 %	367.88 %
Total Assets in million	104	136	154	153	162
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-46	-43	-48	-48	0
Annual Return On Assets	-44.67 %	-31.72 %	-30.77 %	-31.42 %	0 %

AVXL's 5 Years Annual ROA >> Back to AVXL Management Effectiveness >> Compare AVXL ROA to its Competitors

More Return On Assets Ratios
AVXL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AVXL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AVXL's Competitors
Subscribers only: Roa for Anavex Life Sciences 's Suppliers
Subscribers only: Return On Assets for AVXL's Customers

You may also want to know
AVXL's Roi	AVXL's Inventory Turnover Ratio	AVXL's Growth Rates	AVXL's Dividend Comparisons
	AVXL's Profitability Ratios	AVXL's Asset Turnover Ratio	AVXL's Dividend Growth
AVXL's Roe	AVXL's Valuation Ratios	AVXL's Financial Strength Ratios	AVXL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-29T02:43:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.